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ANTXR1Tumor endothelial marker 8 (TEM8) is an integrin-like cell surface protein upregulated on tumor blood
vessels and a potential vascular target for cancer therapy. Here, we found that the ability of an anti-TEM8
antibody, clone SB5, to recognize the extracellular domain of TEM8 on the cell surface depends on other host-
cell factors. By taking advantage of SB5's ability to distinguish different forms of cell surface TEM8, we
identiﬁed alpha-smooth muscle actin and transgelin, an actin binding protein, as intracellular factors able to
alter TEM8 cell surface structure. Overexpression of either of these proteins in cells converted TEM8 from an
SB5-exposed to an SB5-masked form and protected cells from SB5-saporin immunotoxins. Because the
predominant form of TEM8 on the cell surface is not recognized by SB5, we also developed a newmonoclonal
antibody, called AF334, which is able to recognize both the SB5-exposed and the SB5-masked forms of TEM8.
AF334-saporin selectively killed TEM8-positive cells independent of TEM8 cell surface structure. These
studies reveal that TEM8 exists in different forms at the cell surface, a structure dependent on interactions
with components of the actin cytoskeleton, and should aid in the rational design of the most effective
diagnostic and therapeutic anti-TEM8 monoclonal antibodies.MG2, capillary morphogenesis
al antibodies; α-SMA, alpha-
B.V.Published by Elsevier B.V.1. Introduction
Tumor endothelial marker 8 (TEM8) is an 85-kDa integrin-like cell
surface receptor that was originally identiﬁed as one of several
unrelated genes (called TEM1-TEM9) overexpressed in vascular
endothelial cells derived from tumor versus normal colorectal tissues
[1]. Subsequent studies have shown that TEM8 is overexpressed in the
blood vessels of a variety of human solid tumor types in addition to
colorectal cancer [1,2]. TEM8 is highly conserved, and mouse TEM8
protein, which shares 98% amino acid identity with human TEM8, is
also overexpressed in mouse tumor vessels [3]. TEM8 was unique
among the original TEMs identiﬁed in that it was not detected in
the angiogenic vessels of adult ovaries, and in TEM8 knockout mice
developmental angiogenesis appeared unaffected [1,2,4]. However, in
tumor challenge studies, tumor growth was impaired in TEM8
knockout compared to wild-type mice [4]. Together, these studies
suggest that host-derived TEM8 promotes pathological but not
physiological angiogenesis. Such speciﬁcity makes TEM8 an appealingtarget for the development of novel anti-angiogenic or vascular
disrupting agents. Indeed, current anti-angiogenic agents, which have
been approved for clinical use, cannot separate physiological and
pathological angiogenesis, and several side effects associated with the
use of these agents have been reported [5].
Insights into the physiological functions of TEM8 are beginning to
emerge. In vitro studies suggest that TEM8 can bind collagens, such as
collagen I and collagen VI, which, in turn, can promote the migration of
endothelial cells [2,6]. Migration of cells on extracellular matrix is
dependent on actin cytoskeleton reorganization, and recent studies
suggest that the TEM8 cytosolic domain may link extracellular matrix
molecules to the actin cytoskeleton [7,8]. However, it is unclear which
components of the actin cytoskeleton are involved in binding TEM8
under physiological conditions, and how this binding contributes to
TEM8 function. TEM8 may also be involved in collagen uptake through
anendocytosis-mediated degradation pathway, as TEM8knockoutmice
are viable but display an excess buildup of collagen in select organs [4].
TEM8 shares 58% amino acid identity with CMG2, another cell
surface receptor that binds extracellular matrix (ECM) proteins, in
this case laminin and collagen type IV [9]. Both TEM8 and CMG2 share
an integrin-like von Willebrand factor A domain in their extracellular
region. TEM8 and CMG2 have both been found to bind anthrax toxin
proteins [10,11] and have therefore been given the alternative names
anthrax toxin receptor 1 (ANTXR1) and ANTXR2, respectively.
40 M.Y. Yang et al. / Biochimica et Biophysica Acta 1813 (2011) 39–49Protective antigen (PA) is the subunit of anthrax toxin responsible for
binding TEM8 or CMG2, and the PA–receptor interaction is critical for
toxin entry into cells.Owing to its high expression in tumor versus normal vessels, TEM8
has been considered as a potential target for anti-tumor therapy based
on an anti-angiogenic or vascular targeting approach [12]. Several
41M.Y. Yang et al. / Biochimica et Biophysica Acta 1813 (2011) 39–49recent preclinical studies support the idea that TEM8 functions to
promote tumor growth and that inhibition of TEM8 may represent a
useful anti-tumor strategy. First, a soluble TEM8–Fc fusion protein
containing the extracellular domain of TEM8 fused to the Fc region of
mouse IgG was found to have potent tumoricidal activity against a
variety of human tumor xenografts, presumably by competing for
endogenous TEM8 ligand(s) [13]. Second, DNA vaccines against TEM8
have slowed tumor growth in vivo [14,15]. Third, melanoma tumor
growth was found to be impaired in TEM8-deﬁcient mice [4]. Finally,
anthrax toxin proteins have been shown to possess potent tumor-
icidal activity in a number of preclinical studies when judiciously
administered at sub-toxic doses [16–18], an activity that appears to be
mediated primarily through targeting of the tumor vasculature
[19,20]. Although TEM8, CMG2, or both receptors may be responsible
for the anti-tumor activity of anthrax toxin proteins, antibody-based
therapeutics directed against a single receptor could potentially have
similar efﬁcacy with less toxicity.
In exploratory studies aimed at identifying anti-TEM8 antibodies
that may be useful for vascular targeting, we evaluated various
antibodies developed against the extracellular domain of TEM8
including those commercially available and the so-called SB series of
anti-TEM8 mAbs [2]. Surprisingly, none of the antibodies tested
recognized the predominant form of TEM8 expressed on the surface
of live cells, although someof the SB antibodies could recognize a cryptic
population of TEM8-expressing cells. Based on its similarity to integrins,
which are known to harbor both open and closed conformations, we
hypothesized that TEM8may also have more than one conformation at
the cell surface, and that its conformation may be regulated by the
expression of other host-cell factors. Here, we set out to identify these
host-cell factors byusing the SB5 antibody in anunbiasedgenetic screen
and identiﬁed components of the actin cytoskeleton as critical
dominant-acting factors capable of regulating TEM8 structure at the
cell surface. We also describe a new anti-TEM8 antibody, called AF334,
that is able to recognize all forms of TEM8on the surface of live cells and
is a potential tool for TEM8-based therapeutic targeting.
2. Materials and methods
2.1. Cell lines and culture conditions
293 Cells, DLD-1, SK-BR-3, HUVEC, and T/G HA-VSMC were from
ATCC; HT29 was from the DCTD Tumor Repository at NCI (Frederick,
MD); HAECs were from Coriell (Camden, NJ); HMECs were from the
CDC (Atlanta, GA); and coronary SMC and uterine SMC were from
Lonza (Walkersville, MD). CHO-PR230 (CHO) cells, CHO/TEM8 cells,
and CHO/CMG2 cells, a generous gift from Dr. Stephan H. Leppla,
NIAID, were maintained in Ham's F12 medium supplemented with
10% FBS unless indicated otherwise. Endothelial cells were cultured in
EBM-2 (Lonza), smooth muscle cells in SmGM-2, (Lonza), and all
other cells in DMEM supplemented with 10% fetal bovine serum.
Endothelial and smooth muscle cell purity was conﬁrmed by RT-PCR
using various lineage-speciﬁc markers as described in Fig. 5.
2.2. Incorporation of a FLAG-tag onto TEM8
A two-step PCR-based strategywas used to incorporate a 3x-FLAG-
tag onto the N-terminus of TEM8 immediately following the signalFig. 1. SB antibodies recognize TEM8 at the cell surface following selection with SB5 antibod
and the amino acid (aa) region of TEM8 (GenBank No. AF279145) containing the SB epitope
C, Western blot showing strong reactivity of SB5 with an ~85-kDa product from a stable TEM
the pool. D, SB5 mAbs failed to detect TEM8 on the surface of 293 or 293/TEM8 cells by ﬂow
SB5) were strongly labeled (D, upper panel). AF334 anti-TEM8 antibody was able to
immunoﬂuorescence staining demonstrates lack of reactivity of SB5 with 293/TEM8 cells, b
both 293/TEM8 and 293/T8-SB5 cells (red) and co-localized with the SB5 signal in 293/T8-
(blue) revealed similar cell numbers in each group. F, Smaller products of ~35 to 50 kDa we
human (293/T8-SB5) TEM8.peptide. In the ﬁrst step, two separate PCR products were generated
on either side of the FLAG insertion site using as template a TEM8/
pcDNA3.1 vector containing a CMV-driven full-length human TEM8
cDNA (sv1 isoform, GenBank Acc. # AF279145). The primers used for
product A were A-For: 5′-AGGCGTGTACGGTGGGAG-3′ and A-Rev: 5′-
CTTGTCATCGTCATCCTTGTAATCGATGTCATGATCTTTATAATCACCGT-
CATGGTCTTTGTAGTCCCCGGCGCAGATGAGC-3′ and for product B
were B-For: 5′-GATTACAAGGATGACGATGACAAGCAAGGGGGACG-
CAGGG-3′ and B-Rev: 5′-CTGGTGAAGTTGATGCAGCG-3′. The primers
included a 3x-FLAG tag DNA sequence as indicated by bold lettering,
and a small 24 bp complementary region of overlap between the two
products (underlined). After PCR ampliﬁcation, the two PCR products
were gel puriﬁed, mixed, and used as a template in a second PCR
reaction that utilized the outside primers: A-For and B-Rev. The
resultant PCR product containing the FLAG sequence, product C, was
then digested with the restriction enzymes BamH1 and EcoR1 and gel
puriﬁed to remove the amplicon ends. The parent TEM8/pcDNA3.1
vector was also digested BamH1 and EcoR1, and the vector backbone
gel puriﬁed. The PCR-generated puriﬁed product C was cloned into
the vector backbone, and the resulting plasmid, called 3x-FLAG-T8/
pcDNA3.1, was veriﬁed mutation-free by DNA sequencing.
2.3. Immunomagnetic bead selection
SB5 was biotinylated (Thermo Fisher Scientiﬁc, Rockford, IL) and
mixed with Streptavidin M-280 magnetic Dynabeads (Invitrogen,
Carlsbad, CA) to generate SB5-beads. Prior to positive cell selection
with SB5-beads, cells were pre-incubated with streptavidin-beads
pre-bound to biotin-labeled non-speciﬁc IgG to remove any non-
speciﬁc binders. Following positive selection, cells were expanded and
passaged until no bead-bound cells were visible, and the selectionwas
repeated until all cells were SB5-positive by ﬂow cytometry.
2.4. Immunoblotting
Immunoblotting was performed as previously described [2].
Partial epitope mapping of the SB2, SB4, SB8, and SB12 mAbs was
performed using GST-TEM8 peptide deletions as described for SB5 [4].
To evaluate cross-reactivity with CMG2, cellular lysates were derived
from CHO-PR230 (CHO) cells, CHO/TEM8 cells, and CHO/CMG2 cells.
To evaluate cross-reactivity with mouse TEM8, mTEM8 cDNA was
cloned into the pcDNA3.1/neo expression vector (Invitrogen), sequence
veriﬁed, and stably transfected into 293 cells.
2.5. Immunoprecipitation
αSMA was cloned into the expression vector pcDNA3.1/hygro
(Invitrogen) and stably transfected into 293/T8-SB5 cells. Total cell
lysates were incubated overnight with SB5 anti-TEM8 antibodies,
anti-αSMA antibody (Sigma, St. Louis, MO), or nonspeciﬁc mouse IgG
control antibody at 4 °C. Protein G-agarose beads (Roche, Indianapo-
lis, IN) or streptavidin agarose beads (Sigma) were added and
incubated at 4 °C for 2 h. Precipitated proteins were separated by
SDS-PAGE and detected by immunoblotting with either SB5 anti-
TEM8 antibody, anti-αSMA antibody, or anti-FLAG antibody (Sigma,
M2 clone) followed by HRP-anti-mouse IgG F(ab')2 fragment speciﬁc
(Jackson Immunoresearch).ies. A, Table showing SB antibody isotypes, cross-reactivity with homologous proteins,
s. B, ELISA used to measure reactivity of SB mAbs with soluble AP–TEM8 fusion protein.
8 transfected pool (293/TEM8), or a high expressing clone (293/TEM8c1) derived from
cytometry whereas 293/TEM8 cells selected with SB5 immunomagnetic beads (293/T8-
detect TEM8 on both 293/TEM8 and 293/T8-SB5 cells (D, lower panel). E, Co-
ut strong reactivity (green) with 293/T8-SB5 cells. AF334 anti-TEM8 antibody stained
SB5 cells (merged yellow stain). Co-immunoﬂuorescence staining of nuclei with DAPI
re observed in SB5-selected 293 cells expressing exogenous mouse (293/mT8-SB5) or
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293, 293/TEM8c1, or 293/T8-SB5 cells grown on poly-D-lysine-
coated plates were rinsed with cold PBS and labeled with 0.5 mM
sulfo-NHS-SS-biotin (Thermo Scientiﬁc- Pierce) in cold PBS for 40 min
at 4 °C according to the manufacturer's protocol. Immunoprecipita-
tion and immunoblotting of biotinylated proteins were performed as
outlined above (Sections 2.4 and 2.5).
2.7. Immunoﬂuorescence
Cells grown on poly-L-lysine-treated chamber slides were chilled
on ice and SB5 anti-TEM8 or anti-FLAG mAbs (M2 clone) were added
directly to the growth medium for 30 min at 4 °C. Cells were washed
with cold medium, ﬁxed in cold 4% paraformaldehyde in PBS, and
labeled with FITC-conjugated goat anti-mouse IgG. To detect TEM8
with SB5 (a mouse IgG1κ) and AF334 (a mouse IgMκ) simultaneously,
in this case the primary antibodies were detected with either a
DyLight 488-conjugated goat anti-mouse IgG1, Fcγ-speciﬁc (Jackson,
cat # 115-485-205) or a DyLight 594-goat anti-mouse IgM, μ chain-
speciﬁc antibody (Jackson, cat # 115-515-075). For dual-color
staining of exogenous TEM8 and αSMA, stably transfected 293/
FlagT8-SB5/αSMA cells were incubated with rat-anti-FLAG antibodies
(Biolegend), permeabilized with 0.1% Triton-X 100, then incubated
with mouse anti-α-SMA mAbs followed by a secondary layer of FITC-
linked goat anti-rat and biotin-linked donkey anti-mouse IgG
(Jackson) and a third layer of 488-linked donkey anti-FITC and
Texas red-streptavidin (Vector). The speciﬁcity of staining was
veriﬁed using the same staining strategy on parent 293 and 293/
FlagT8-SB5 cells or by substituting the primary antibodies for isotype
matched non-speciﬁc IgGswhen staining 293/FlagT8-SB5/αSMA cells.
Sections were counterstained with DAPI and immunoﬂuorescent
images captured using a Nikon Eclipse E600 microscope or a Zeiss
LSM510 confocal microscope.
2.8. TEM8 internalization experiment
SB5 or control IgG labeled with Cy5.5 (Thermo Fisher Scientiﬁc)
was added to the culture medium of cells grown on poly-L-lysine-
treated chamber slides and incubated at 37 °C for 3 h. On ice, cells
were rinsed with PBS, ﬁxed with 4% paraformaldehyde, and TEM8
present on the cell surface was detected by post-staining with FITC-
conjugated goat anti-mouse IgG antibody.
2.9. Identiﬁcation of genes that regulate SB5-toxin sensitivity by
expression cloning
An MMLV-based cDNA library from uterus (ViraPortXR, Strata-
gene, Santa Clara, CA) was prepared and used to infect exponential-
phase 293/FlagT8-SB5 cells on ten 100-mm plates according to the
manufacturer's recommendations. Virus infected FlagT8-SB5 cells
were treated with 40 nM TSA overnight, then with biotinylated-SB5
and 5 nM saporin–streptavidin [Advanced Targeting Systems (ATS),
San Diego, CA]. Surviving colonies were expanded and selected with
magnetic Dynabeads (Pan-mouse IgG, Invitrogen) that had been pre-
armed with anti-FLAG mAbs. After repeating the SB5-toxin treatment
and SB5-bead selection once more, surviving cells were cloned by
limiting dilution and genomic DNA from each clone was isolated using
the DNeasy blood and tissue kit (Qiagen, Gaithersburg, MD). Each insert
was identiﬁedbyPCRusing theprimer pair, F: CAGCTTGGATACACGCCG,
and R: TGCCAAACCTACAGGTGGG.
2.10. Cell viability assay
Cells were plated on poly-L-lysine-treated 96-well plates over-
night. The next day, biotinylated SB5 and saporin–streptavidin,mouse anti-FLAG mAbs, and anti-mouse-IgG saporin conjugates
(Mab-ZAP, ATS), or AF334 anti-TEM8 antibodies and anti-mouse
IgM-saporin (Anti-M-ZAP, ATS) were pre-incubated together at RT
for 20 min and then added to cells. Seventy-two hours later, medium
was replaced with fresh medium containing 10% AlarmarBlue
(Invitrogen) and ﬂuorescence measured at 560 nm/590 nm (Ex/Em)
in a spectrophotometer 4 h later. Brightﬁeld images were captured
72 h or 96 h post-treatment.
2.11. Flow cytometry
Following trypsinization, at 4 °C cells were rinsed in PBS/0.5%BSA
(PBS/BSA), incubated in PBS/BSA containing primarymAbs, rinsed, in-
cubatedwith PBS/BSA containing FITC-conjugated secondary (Jackson
Immunoresearch, West Grove, PA), rinsed, and analyzed on a FACS-
Calibur ﬂow cytometer (Becton Dickinson, Franklin Lakes, NJ).
2.12. RT-PCR
RT-PCR was performed using total RNA isolated from cells using
RNeasy mini kit (Qiagen), and cDNA was synthesized using
Superscript III 1st strand synthesis system (Invitrogen). The primer
pairs used were vWF-F: CGGCAGGTCATCCACGG, vWF-R: CGGA-
CAGCTTGTAGTACCCAG; VE-Cad-F: TGCTAACCCTGCCCAACG, VE-Cad-
R: CCTCTCAATGGCGAACACG; PDGFRβ-F: TGTCCCTGTCCGAGTGCTG,
P D G F R β - R : C C A GGA T GG C T G AGA T C A C C ; T A G L N - F :
CCCATCCTGTCTGTCCGAAC, TAGLN-R: CACGCCATTCTTCAGCCAG; α-
SMA-F: GCCGACCGAATGCAGAAG α-SMA-R: GGACATTCA-
CAGTTGTGTGCTAG; TEM8-F: GCCAACGGTAGACGCCTC, TEM8-R:
TAGGACCCACAAGGCATCG; Eif4H-F: CGTAGCCAGAAGGAGTTGCC,
Eif4H-R: ATGTCCACACGAAGTGACCG.
2.13. Generation of AF334 Anti-TEM8 mAb
CHO cells and CHO cells transfected with full-length human TEM8
(CHO/TEM8) [21] were maintained in alpha MEM supplemented with
glutamine, gentamicin, HEPES, and hygromycin. CHO/TEM8 cells were
enriched for high surface expression of TEM8 by three sequential
rounds of ﬂow cytometry sorting (BD FACSAria) by staining cells with
PA. PA was prepared as described [22] and conjugated with sulfo-
NHS-LC-biotin using a kit (Thermo Fisher Scientiﬁc). Cells were
labeled in 0.5 ml PBS/1% BSA on ice for 15 min with 10 μg/ml biotin-
PA, rinsed with PBS, incubated with 2 μg/ml streptavidin-R-PE
(BioLegend, San Diego, CA) in PBS/1% BSA, rinsed, and resuspended
with PBS. The highest 6% positive cells were selected in each sort.
2.5 million TEM8 surface-enriched CHO/TEM8 cells were adminis-
tered by intraperitoneal injection in 0.2 ml PBS monthly to BALB/c
female 2-month-old mice. Monthly inoculations were repeated three
additional times and splenocytes harvested 3 days after the last boost.
Splenocytes were fused 1:1 with OUR-1mousemyeloma cells in Opti-
MEM in the presence of 50% PEG (Invitrogen) following the
manufacturer's protocol. Hybridomas were grown in Opti-MEM
supplemented with HAT and 10% FBS. Supernatants were screened
by differential ﬂow cytometry binding to CHO/TEM8 versus CHO cells
using FITC-conjugated goat anti-mouse Ig (Invitrogen). A secondary
screen was done using an enzyme-linked immunoassay with
membrane preparations made by sonication of CHO or CHO/TEM8
cells as previously described [22]. The hybridoma showing the highest
supernatant reactivity was subcloned three times by limiting dilution,
expanded, cryopreserved, and designated AF334. The AF334 hybrid-
oma produced an IgMκ, which reacted speciﬁcally with CHO/TEM8
but not CHO or CHO/CMG2 cells by ﬂow cytometry. AF334 also
reactedwith both 293/mTEM8 and 293/hTEM8 cells, but not 293 cells,
demonstrating cross-reactivity with the mouse protein. The AF334
hybridoma maintained stable expression after weaning into serum-
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and antibodies were puriﬁed by gel ﬁltration.
3. Results
3.1. SB antibodies are speciﬁc for TEM8 and recognize the soluble
extracellular domain
A panel of mouse mAbs, the “SB” series, was previously developed
against the full extracellular domain of human TEM8 using puriﬁed
recombinant proteins [2]. To determine if thesemAbs cross-react with
the mouse TEM8 protein (mTEM8), we tested them by Western
blotting using lysates of 293 cells transfected with a full-length
mTem8 expression vector. Four of the ﬁve mAbs tested, called SB2,
SB4, SB5, and SB12, reacted with both mouse and human TEM8,
whereas SB8 was human-speciﬁc (Fig. 1A). High cross-species
reactivity is not unexpected given the high level of similarity (98%)
between the mouse and human proteins. We also tested SB mAbs by
Western blotting against cells transfected with CMG2, the closest
homologue of TEM8, and found that none of the mAbs cross-react
(Fig. 1A).
Next, we developed a capture ELISA to determine if any of the SB
mAbs could bind the native extracellular domain of TEM8 fused to
alkaline phosphatase (AP-TEM8). Although several mAbs were able to
bind soluble AP–TEM8 fusion protein, SB5 bound best and none of the
mAbs reacted with the control proteins AP–TEM7 or AP alone
(Fig. 1B). SB5 antibody also worked best for Western blotting and
immunoprecipitation of TEM8, without any apparent cross-reactivity
to other proteins [see Fig. 1C and [1]]. However, each of the SB mAbs
failed to detect signiﬁcant levels of cell surface TEM8 on 293 cells
stably transfected with a full-length TEM8 expression vector (293/
TEM8; Fig. 1D and E). We also tested several commercially available
antibodies each of which failed to detect native TEM8 at the cell
surface.1 The lack of cell surface staining was not cell type speciﬁc
because these antibodies also failed to detect TEM8 on the surface of
TEM8-positive primary endothelial cells and TEM8 transfected CHO
cells.1 Despite this lack of staining, TEM8 was presumably present on
the surface of 293/TEM8 cells based on cell surface labeling with non-
permeable biotin (Fig. S1) and subsequent studies that employed a
tagged version of the receptor and a newly developed antibody (see
below). Based on this, we hypothesized that the epitope for SB5 and
other currently available anti-TEM8 antibodies is normally masked on
the surface of 293/TEM8 cells.
3.2. SB5 antibodies recognize a cryptic subpopulation of 293/TEM8 cells
While performing immunoﬂuorescence staining for cell surface
TEM8 in 293/TEM8 cells using SB5 antibodies, we noticed a very small
fraction of the cells (b0.5%) were strongly positive, while 293 parent
cells were completely negative. These positive cells were not apparent
by ﬂow cytometry analysis due to their low frequency. In order to
determine if this rare fraction of the 293/TEM8 parent population
could be enriched, we puriﬁed these cells using SB5-linked magnetic
beads. After expanding the SB5-bead bound cells in culture and
repeating the selection and expansion 3 more times, we were able to
obtain a variant subline, called 293/hT8-SB5, that uniformly reacted
with SB5 mAbs by both immunoﬂuorescence and ﬂow cytometry
(Fig. 1D and E). Likewise, when we repeated the SB5 selection using
293 cells transfected with mouse TEM8 (293/mT8-SB5) again we
were able to derive sublines, this time with mTEM8 detectable on the
cell surface, while parallel control selections performed on parent 293
cells failed to result in any enrichment. Importantly, SB8 human-
speciﬁc anti-TEM8 mAbs labeled the cell surface of 293/hT8-SB5 cells1 Mi Young Yang and Brad St. Croix, unpublished observations.similar to SB5 (Fig. S2) but failed to detect mouse TEM8 on the surface
of 293/mT8-SB5 cells.1 Because SB5 and SB8 recognize independent
epitopes, this result conﬁrmed the speciﬁcity of these antibodies for
TEM8. Preliminary mapping of the SB antibody binding sites using
peptide deletions of the TEM8 extracellular domain revealed that SB5
and SB8 mAbs recognize distinct epitopes separated by at least 123
amino acids (Fig. 1A). Immunoblotting with several independent SB
mAbs also revealed smaller 35 to 50-kDa products in the SB5-selected
cells (Fig. 1F), which presumably represent intracellular degradation
products of the TEM8 extracellular domain because these fragments,
unlike the full-length 85-kDa product, were not labeled with biotin
immediately following cell surface biotinylation (Fig. S1). Throughout
these studies, the small TEM8 fragments were always observed in
cells that displayed surface-exposed SB5 binding sites, but never in
cells with an SB5-masked form of TEM8, thus providing an index of
SB5 accessibility.
3.3. SB5 anti-TEM8 antibodies are internalized
Anthrax toxin proteins bind TEM8 or CMG2 and are taken up into
cells through a highly regulated endocytosis-mediated process
[23,24], but internalization of anti-TEM8 antibodies has not yet been
described. To determine if SB5mAbs could be taken up by 293/T8-SB5
cells, we labeled SB5 with Cy5.5 and followed its uptake in live cells.
Cy5.5-SB5 (red channel) could be readily observed inside cells as early
as 30 min following treatment, and most was taken up into the cells
by 3 h (Fig. 2A). Some Cy5.5-SB5 signal (red) could also be detected on
the surface 3 h following internalization, which was veriﬁed by ﬁxing
the cells and amplifying the surface bound Cy5.5-SB5 signal with a
FITC-labeled anti-mouse secondary antibody (green).
To determine if 293/T8-SB5 cells were sensitive to anti-TEM8
immunotoxin, we treated cells with biotinylated SB5 antibody and
streptavidin–saporin. Saporin is a type I ribosome-inactivating
protein that has no known speciﬁcity in mammalian cells and can
be internalized only if conjugated to an appropriate antibody.
Seventy-two hours following treatment with 1 nM of SB5–saporin
toxin, viability of 293/T8-SB5 was reduced by ~70% while both 293
and 293/TEM8 cells were unaffected at this concentration (Fig. 2B).
Thus, saporin-conjugated SB5 mAbs are selectively toxic to 293/T8-
SB5 cells following binding and internalization.
3.4. Development of a genetic screen to identify host-cell factors that
regulate TEM8 structure
The above results suggested that the predominant form of TEM8
on the cell surface contains a masked SB5 binding site. Based on this,
we hypothesized that additional factors may be present in 293/TEM8
cells, which are reduced or absent from SB5-selected 293/T8-SB5 cells
and are required for maintenance of TEM8 in its SB5-masked state. For
example, additional TEM8 binding proteins present in 293/TEM8 cells,
which could be cytosolic, membrane, or extracellular, may facilitate a
conformational change in TEM8, which masks the SB5 binding site.
Alternatively, a membrane spanning or extracellular binding partner
may interact with TEM8 and directly block the SB5 antibody/epitope
interaction. To identify dominant-acting factors that can regulate SB5
binding, we designed a phenotypic screen based on sensitivity of SB5-
selected 293 cells to SB5 immunotoxins. The assay involved the
transfer of a retroviral cDNA library derived from an SB5-toxin-
resistant (SB5-masked) cell line into a sensitive (SB5-exposed) cell
line, selection with SB5-bound toxin, recovery of surviving colonies
and the identiﬁcation of individual cDNAs, which can rescue cells from
toxicity (Fig. 2C). We initially considered using the parental 293/T8-
SB5 cell line, or clones of this cell line, as “sensitive” recipients for
infection. However, when we exposed the parental 293/T8-SB5 stable
pool or multiple independent clones derived from this pool to toxin,
we consistently found that a small subpopulation of the treated cells
Fig. 2. SB5–saporin immunotoxins are internalized and selectively kill 293/T8-SB5 cells. A, Cy5.5-labeled SB5 (red) was taken up into 293/T8-SB5 cells after 3 h at 37 °C. Some of the
Cy5.5-SB5 label was detected on the cell surface following the 3 h incubation, which was conﬁrmed by post-incubation staining with FITC-labeled secondary mAbs (green). The
secondary antibody only recognizes primary Cy5.5-SB5 antibody that is present at the cell surface and provides extra sensitivity because of the added layer of ampliﬁcation. Although
some Cy5.5-SB5 antibody was detected at the cell surface, much of the primary antibody had clearly internalized (red, bottom right panel). B, 1 nM or 10 nM of saporin–streptavidin
toxin combined with biotin-labeled SB5 selectively killed 293/T8-SB5 cells (bottom panel) compared to saporin–streptavidin alone (top panel). C, Strategy for identiﬁcation of genes
that regulate SB5-toxin sensitivity.
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surviving cells were expanded in culture for 2 weeks and then tested
for TEM8 expression by ﬂow cytometry and Western blotting, TEM8
expression was near background levels (Fig. 3C and D). Although this
result conﬁrmed the remarkable speciﬁcity of the SB5mAbs for TEM8,
it also suggested that loss of TEM8 expression may lead to an
excessive number of background colonies in our cDNA expressionscreen and prompted us to explore possible mechanisms regulating
the loss of TEM8 expression in SB5-toxin selected cells. Because TEM8
expression was lost in clones of 293/T8-SB5 which originated from
single cells (Fig. 3D), we reasoned that TEM8 expression in these
surviving cells may have been silenced epigenetically, as reported for
other genes [25]. To test this, we treated the toxin-selected 293/T8-
SB5 cells, which had lost TEM8 expressionwith Trichostatin A (TSA), a
Fig. 3. A fraction of the 293/T8-SB5 cell line and its clonally derived sublines survive saporin-SB5 immunotoxin treatment by epigenetic silencing of TEM8 expression. A, 293, 293/T8-
SB5 (pool), 293/T8-SB5-clone5, or 293/T8-SB5-clone19 cells were untreated (control) or treated with biotinylated SB5 mAbs and 0.5 nM or 5 nM of saporin–streptavidin and cell
viability was measured 72 h later. The percent viability of the clones was similar to that of the pool. B, A similar number of surviving 293/T8-SB5 cells from the pool or its clonally
derived sublines were observed by Brightﬁeld microscopy 96 h post-treatment with SB5mAbs and 1 nM of saporin–streptavidin. C, Flow cytometry staining with SB5mAbs revealed
a signiﬁcant reduction in TEM8 expression on the cell surface of the 293/T8-SB5 pool (top panel) or a clone derived from this pool (293/T8-SB5-c5; bottom panel) 2 weeks following
treatment with 5 nM of SB5–saporin immunotoxin. D, Immunoblotting (IB) for TEM8 revealed a loss of TEM8 expression in toxin-treated surviving cells from the 293/T8-SB5 pool or
its subclones (clone 5 and clone 19). In this experiment, cells were treated either twice with 0.5 nM of toxin 3 days apart (0.5+0.5), twice with 1 nM of toxin 3 days apart (1+1), or
once with 5 nM of SB5–saporin (5). Two weeks later, cells that had recovered were analyzed byWestern blotting. E and F, Trichostatin A (TSA) treatment for 24 h resulted in a dose-
dependent rescue of TEM8 expression in the toxin-treated surviving fraction of 293/T8-SB5 clone 5 (c5-SF) and clone 19 (c19-SF) as detected by Western blotting (E) or ﬂow
cytometry (F).
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on the cell surface in a in a dose-dependent manner (Fig. 3E and F),
suggesting that TEM8 expression is regulated by histone acetylation.
Because TSA itself demonstrated some toxicity at the concentra-
tion needed to recover full TEM8 expression, we considered using
positive selection with anti-TEM8 immunomagnetic beads as an
additional method to ensure the maintenance of TEM8 expression on
the surface of all recipient SB5-toxin treated cells. Because each of the
SB mAbs and others commercially available were unable to detect theSB5-masked form of TEM8, we incorporated a 3x-FLAG tag into the N-
terminus of TEM8. Immunoﬂuorescence staining using anti-FLAG
mAbs revealed FLAG-TEM8 on the cell surface of non-permeabilized
293/FlagT8 cells immediately following transfection (Fig. 4, bottom
panel). As expected, however, SB5 staining remained undetectable by
ﬂow cytometry, and SB5 only labeled the occasional cell by
immunoﬂuorescence staining (Fig. 4, top panel). Next, we repeated
our selection of 293/FlagT8 cells using SB5-linkedmagnetic beads, and
then cloned the selected cells by limiting dilution. One of the clones,
Fig. 4. Anti-FLAG antibodies recognize N-terminal FLAG-tagged TEM8 on the cell
surface without the need for cell surface enrichment. FLAG-tagged TEM8 could be
detected in the majority of 293/FlagT8 cells using anti-FLAG mAbs immediately
following transfection (green, left panel, bottom) whereas SB5 anti-TEM8 mAbs could
only detect sporadic cells. However, both anti-FLAG and SB5mAbs could detect TEM8 in
293/FlagT8-SB5 cells, which had been selected with SB5 immunomagnetic beads (right
panel). Nuclei from the same region were visualized with the DAPI (blue) ﬁlter.
Table 1






ACTA2 Actin, alpha2, smooth muscle, aorta (α-SMA) Y 1, 2, 3, 4
TAGLN Transgelin Y 1, 3, 4, 8
ARL1 ADP-ribosylation factor-like 1 N 7, 8, 9
ACTG2 Actin, gamma 2, smooth muscle enteric Y 7, 10
APOD Apolipoprotein D N 1, 6
COL6A2 Collagen, type VI, alpha 2 N 6, 9
GSN Gelsolin Y 6, 7
MYL9 Myosin, light chain 9, regulatory Y 1, 4
RPS6 Ribosomal protein S5 N 1, 3
SMARCB1 SWI/SNF related, matrix associated,
actin dependent regulator of chromatin
Y 7, 8
TPM2 Tropomyosin 2 (beta) Y 5, 10
TPT1 Tumor protein, translationally controlled 1 N 2, 9
a Clones were isolated from 10 independent plates that were infected with virus
separately.
Fig. 5. TEM8 is expressed by both smooth muscle cells and endothelial cells. RT-PCR
revealed expression of TEM8 in both endothelial cells (HAEC, HMEC, and HUVEC) and
smoothmuscle cells (coronary, uterine, and T/G HA-VSMC) but not in colon (DLD-1 and
HT29) or breast (SK-BR-3) tumor cells lines. The smooth muscle cell marker PDGFR-β
and the endothelial markers von Willebrand factor (vWF) and VE-cadherin (VE-CAD)
were used to conﬁrm the purity of the cells. Eukaryotic translation initiation factor 4H
(EIF4H) was used as a loading control.
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cDNA expression library.
To identify genes in our screen, 293/FlagT8-SB5 recipient cells
were infected with a retroviral cDNA library derived from uterus, a
tissue that expressed high levels of TEM8, and then treated with 40
nM TSA, a concentration found in our earlier studies to be minimally
toxic to the cells, followed by saporin-linked SB5. Importantly, the
number of surviving colonies on each plate was 10-fold or higher in
transduced versus non-transduced cells, suggesting a successful
rescue by the cDNA library. After sorting cells with anti-FLAG-
conjugated magnetic beads and repeating the toxin/TSA selection and
sorting once more, cDNA was recovered from surviving clones and
identiﬁed by DNA sequencing.
3.5. Genetic screen reveals multiple components of the actin cytoskeleton
A total of 99 cDNA inserts originating from 10 independent plates
were recovered and sequenced, and 12 genes were identiﬁed two or
more times (Table 1). Interestingly, 7 of the top 12 genes identiﬁed
(~60%) are known to be directly or indirectly involved in regulation of
the actin cytoskeleton. The most frequently observed genes were
transgelin (TAGLN, SM22α) and alpha-smooth muscle actin (α-SMA,
ACTA2), each identiﬁed 4 times from 4 independent plates. Transgelin
is known to promote the cross-linking or “gelling” of actin and, similar
to α-SMA, is thought to be important for contraction of smooth
muscle cells [26–28].Several of the identiﬁed genes, including smooth muscle actin and
transgelin, are known to be expressed predominantly by vascular
pericytes or smooth muscle cells. However, TEM8 was originally
identiﬁed in a screen for genes overexpressed in tumor endothelial
cells [1]. To determine if proliferative vascular smooth muscle cells
also express TEM8, we evaluated TEM8 mRNA expression in cultured
Fig. 6. Exogenous expression of transgelin or α-SMA rescues 293/FlagT8-SB5 cells from SB5–saporin toxicity. A, 293, 293/FlagT8-SB5, or 293/FlagT8-SB5 cells expressing transgelin
(FlagT8-SB5/TAGLN) orα-SMA (FlagT8-SB5/α-SMA) were untreated (control) or treated with SB5–biotin and saporin–streptavidin (SB5-toxin) and cell viability wasmeasured 72 h
later. B, Following toxin treatment, transgelin- or α-SMA-expressing cells from (A) appeared similar to the untreated controls. C, Flow cytometry revealed a lack of SB5 labeling in
293/FlagT8-SB5/TAGLN or FlagT8-SB5/α-SMA cells (top panel). However, cell surface TEM8was detected in the same cells using anti-FLAGmAbs (middle panel) or AF334 anti-TEM8
antibodies (bottom panel). D, TEM8 expression was maintained in 293/FlagT8-SB5 cells following transfection with TAGLN orα-SMA in cellular lysates analyzed by immunoblotting
(IB) with SB5 antibodies. Non-speciﬁc bands were observed on the same blot upon re-probing with different antibodies and served as an internal loading control (CTRL). E, TEM8was
co-immunoprecipitated with α-SMA using anti-α-SMAmAbs but not with control IgGmAbs. F, Immunoﬂuorescence staining of FlagT8-SB5/α-SMA cells with anti-α-SMA (red) and
anti-FLAG antibody (green) revealed co-localization (merge, yellow) particularly in focal spots at the periphery of cells.
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comparison, included three tumor cell lines of epithelial origin. TEM8
was found to be expressed in both vascular pericytes and endothelial
cells, while expression was undetectable in the tumor cells analyzed
(Fig. 5).
3.6. Transgelin and α-SMA regulate TEM8 cell surface structure
To determine if transgelin or α-SMA was responsible for
mediating resistance to SB5–saporin, we transfected these genes
into 293/FlagT8-SB5 cells and then treated cells with the SB5
antibody-toxin. Importantly, at 5 nM of SB5–saporin, expression of
either transgelin or α-SMA rescued 293/FlagT8-SB5 cells from
toxicity (Fig. 6A and B). An analysis of SB5 binding by ﬂow cytometry
revealed that SB5 was no longer able to bind TEM8 on the surface of
293/FlagT8-SB5 cells following transfection with either transgelin or
α-SMA, even though the parent 293/FlagT8-SB5 cells labeled strongly
(Fig. 6C, top panel). Importantly, however, TEM8 expression
remained high in transgelin or α-SMA transfected 293/FlagT8-SB5
cells by immunoblotting (Fig 6D), and staining of cells with anti-
FLAG mAbs by ﬂow cytometry veriﬁed the expression of TEM8 on the
cell surface of 293/FlagT8-SB5-TAGLN or 293/FlagT8-SB5-SMA cells
(Fig. 6C, middle panel). These results suggest that an alteration in the
structure of TEM8 at the cell surface is responsible for masking the
SB5 epitope.
Next, we set out to determine if an alteration in TEM8 structure
could be the consequence of a direct interaction between TEM8 and
α-SMA or transgelin. Indeed, TEM8 co-immunoprecipitated with α-
SMA (Fig. 6E), and these proteins were also found to co-localize at the
cell surface by immunoﬂuorescence staining (Fig. 6F). Although we
have not yet been able to co-immunoprecipitate transgelin and TEM8,
this could be due to a limitation of the mAbs currently available.
Alternatively, TEM8 may bind transgelin indirectly.
Because the SB5-exposed form of TEM8was derived from a cryptic
population and was only observed on the majority of cells following
cell surface enrichment with SB5-beads, these studies indicate that an
SB5-masked form of TEM8 is generally present on the cell surface of
TEM8-positive cells. To determine if the predominant SB5-masked
form of TEM8 could also be internalized upon antibody binding,
similar to the SB5-exposed form, we treated non-selected 293/FlagT8
cells with saporin-bound anti-FLAG antibodies. Saporin-anti-FLAG
antibodies were selectively toxic to 293/FlagT8 cells compared to
parental 293 cells1 suggesting that antibodies that can recognize theFig. 7. 293/FlagT8 cells (293/TEM8) are sensitive to AF334 anti-TEM8 saporin immunotoxins
AF334 anti-TEM8 mAbs along with 5 nM or 10 nM of saporin-conjugated anti-mouse secon
undergone prior selection with SB5 immunomagnetic beads (pb0.001 at 5 nM, pb0.002 at 1
nM of saporin revealed toxicity only in the AF334 treated 293/TEM8 cells. The relative levelpredominant SB5-masked form of TEM8 on the cell surface can also be
internalized effectively.
3.7. Development of an antibody that recognizes the SB5-masked form
of TEM8
Encouraged by these results, we set out to develop a new anti-
TEM8 monoclonal antibody that can recognize the predominant SB5-
masked form of TEM8. Rather than using recombinant TEM8 protein
as the immunogen, this time one of us (AF) employed an alternative
method for antibody generation based on immunization of mice with
TEM8-expressing cells followed by ﬂow cytometry-based screening
(see Materials and methods for details). Using this strategy, a
monoclonal antibody, called AF334, was identiﬁed that, like SB5,
was able to bind both mouse and human TEM8 by ﬂow cytometry.
AF334 was also able to bind the SB5-exposed form of TEM8 on the
surface of SB5-selected 293/hT8-SB5 cells (Fig. 1E and D, bottom
panel, red). Importantly, however, AF334 differed from previously
developed anti-TEM8 antibodies in that it also reacted strongly with
the predominant SB5-masked form of TEM8 on the cell surface
(Fig. 1D, bottom panel, green, Fig. 1E, and Fig. 6C, bottom panel). Next,
we treated cells expressing the SB5-masked form of TEM8 with an
AF334–saporin immunotoxin. Unlike SB5, AF334 was toxic towards
293/TEM8 cells but not 293 cells (Fig. 7A and B), demonstrating the
ability of this antibody to selectively deliver toxin into cells expressing
the predominant SB5-masked form of TEM8.
4. Discussion
The results of these studies suggest that SB5 recognizes a form of
TEM8 that is normally masked, most likely due to binding of the TEM8
cytosolic domain with components of the actin cytoskeleton. Masking
of the SB5 binding site could, in principle, be caused by oligomeri-
zation of TEM8 at the cell surface facilitated by interactions with the
actin cytoskeleton. However, we favor the hypothesis that TEM8
exists in two alternative conformations, open and closed, based on its
homology with integrins, which also bind ECM and can change their
conformation upon binding to components of the actin cytoskeleton.
Although the exact role of TEM8 remains unclear, binding of TEM8
to components of the actin cytoskeleton could be important
biologically for several reasons. TEM8 has been shown to promote
migration [6], a process known to depend on actin. Alpha-SMA and
transgelin are both important for regulating smooth muscle. A, Cell viability was measured in 293 or 293/TEM8 cells 72 h following treatment with
dary mAbs. Note the AF334-speciﬁc toxicity observed in 293/TEM8 cells that had not
0 nM). B, Brightﬁeld microscopy 72 h post-treatment with SB5 or AF334 followed by 10
of TEM8 on the surface of the 293 or 293/TEM8 cells is shown in Fig. 1D, bottom panel.
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tion. Finally, binding of collagen or other uncharacterized extracellu-
lar ligands to TEM8may result in receptor internalization via an actin-
dependent endocytotic pathway, similar to that exploited by anthrax
toxin proteins.
These studies demonstrate that the potential therapeutic utility of
SB mAbs is compromised by their inaccessibility to full-length TEM8
on the cell surface. Indeed, treatment of tumor-bearing mice with an
anti-TEM8/truncated tissue-factor fusion protein containing the
variable domain of SB5 resulted in only a modest tumor growth
delay [29], a small response considering the striking tumor regres-
sions observed in earlier studies of tissue-factor induced vascular
thrombosis [30]. However, by applying cell-based selection strategies
that employ TEM8-expressing cells as the immunogen, we have been
able to develop a new monoclonal antibody against TEM8, called
AF334, which is able to recognize the predominant form of TEM8 on
the cell surface. AF334–saporin immunotoxins were found to be
selectively toxic to TEM8-expressing cells, similar to anthrax toxin
proteins. However, unlike anthrax toxin proteins, AF334 does not
react with CMG2. Because AF334 only recognizes TEM8, AF334-based
immunotoxins could potentially have an improved speciﬁcity for
tumor vessels compared to anthrax toxin proteins. Saporin is a plant-
derived foreign product and its immunogenicity, like anthrax-based
toxins, may ultimately hinder long-term repeated dosing in mam-
mals. Function-blocking anti-TEM8 antibodies or TEM8 antibodies
conjugated to toxins that are less immunogenic may make more
suitable agents for long-term repeated use in vivo. Further studies are
needed in order to determine the therapeutic potential of AF334 or
AF334-based immunotoxins in preclinical tumor models.
In summary, by employing a genetic screen, we provide direct
evidence that the actin cytoskeleton is able to regulate TEM8 structure
at the cell surface supporting the idea that TEM8, like integrins, may
exist in both open and closed conformations. This study also
demonstrates that TEM8 expression is regulated epigenetically by
histone acetylation, providing a potential new avenue to modulate
anthrax toxin susceptibility. These results have important implica-
tions for understanding the biological role of TEM8 and anthrax toxin
pathogenicity and should aid in efforts to develop the most effective
anti-TEM8 diagnostic and therapeutic mAbs.
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